Research on structural optimization design for shield beam of hydraulic support based on response surface method

Abstract The shield beam is the main load-bearing component of the hydraulic support. The structural optimization design of one shield beam is fulfilled by the response surface method. Using the weight as the objective function, the structural optimization mathematical models of shield beam is set up. The experimental design is performed in the ANSYS software and uniform design. The maximum stresses of shield beam are gotten in the different sizes. The response surface models of design parameters and maximum stresses are fitted by the least squares method. The structural optimization design of shield beam is completed by the random direction method. This research implements the structural optimization design of hydraulic support shield beam in a modern design method, and provides a valuable guidance for the hydraulic support research and development

The Effect of Fucoidan on Cellular Oxidative Stress and the CatD-Bax Signaling Axis in MN9D Cells Damaged by 1-Methyl-4-Phenypyridinium

Background: The purpose of this study was to investigate the impact of fucoidan (FUC) on the oxidative stress response and lysosomal apoptotic pathways in the Parkinson disease (PD) cell model.Methods: The Dopaminergic nerve precursor cell line(MN9D) cells that served as a PD model in this study underwent damage induced by 100 μM 1-methyl-4-phenyl pyridine (MPP+). Cell viability was assessed after FUC treatment and intracellular SOD GSH was measured via immunofluorescence assay. Cellular changes in cathepsin D, Autophagy marker Light Chain 3-II (LC3-II), and apoptotic protein Bax were assessed by Western blot. The expression of Cat D, LC3-II, and B cell lymphoma-2-associated x protein (Bax) was also measured after addition of the cathepsin inhibitor, pepstatin A.Results: The results indicated that MN9D cell viability decreased by 50% within 24 h after 100 μM MPP+ induced toxicity. Pretreatment with 100 μM Fucoidan reduced cellular expression of LC3-II and CatD in 3 h and suppressed the induction of Bax protein. After pepstatin A treatment, Bax expression was significantly downregulated.FUC reversed the reduction of superoxide dismutase (SOD) L-Glutathione(GSH), decreased cell viability, and apoptosis induced by MPP+ in 6 h, suggesting that Fucoidan can attenuate damage to MN9D cells induced by MPP+.Conclusions: Fucoidan protected lysosomes, reduced the expression of LC3-II, inhibited the expression of CatD-Bax and the oxidative stress response, suppressed apoptosis, and thus conferred protective effects for dopaminergic neural cells. FUC may have neuroprotective effects on PD and further research is needed

MULTIBODY NONLINEAR PERFORMANCE ANALYSIS OF POWER TRANSMISSION LINE SPACERS

This paper study on some enhanced spacers and then get it `s static mechanical properties through the finite element analysis software of ANSYS. The research use the horizontal tension and compression load and radial force load that spacer can bear to simulate the conductor icing and short-circuit working condition. The research considered the spacer`s material nonlinear and the advanced contact nonlinearity of spacer multibody systems. Compared with experiment result,it shows that the weakest part is the spacers ` wire clamp. Rubber mat can reduce the collision between components and play a role in energy storage. The research result provide a good reference for the spacers` design、improvement and usage. And it lays the foundation for the fine simulation analysis of transmission line system

NONLINEAR SIMULATION AND EXPERIMENTAL ANALYSIS OF THE PRE-CLAMP OF THE EXTRA HIGH PRESSURE SPACER BARS

The looseness or fall off of the clamp is one of the important factors for the failure of spacer bar. The research on the clamp strength is very important. Based on ANSYS finite element analysis software,non-linear emulation analysis is carried out. A reinforced spacer clamps was chosen as the object,using Mooney-Rivlin rubber constitutive model,simulating clamp for pre-clamping the wire by using pre-rigid displacement and simulating non-uniformloading conditions such as wire icing and winding by applying the tension along the line and rotarytorque load. Compared with experiment result,it shows that the strength and gripping performance of the new clamp satisfies the requirement of DL/T1098-2009,and the clamprubber spacer plays a role in reducing wear and protection. At the same time,the correctness of finite element model of spacer bar clamp is verified. It also provides useful reference for the clamp structure improvements,and lays the foundation for wind-resistant simulation analysis of high-voltage transmission line system

Map-in-Parallel-Coordinates Plot (MPCP): Field Trial Studies of High-Dimensional Geographical Data Analysis

As the world has become increasingly digitalized in recent years, high-dimensional data with geographical location coordinate attributes, mainly referring to latitude and longitude, have been accumulated and spread to many disciplines. It is challenging to analyze such data. The map-in-parallel-coordinates plot (MPCP) is an incorporate visual analysis method that can express, filter, and highlight high-dimensional geographical data to facilitate data exploration and comprehension. In this paper, the MPCP underwent a series of field trial studies to verify its applicability, adaptability, and high efficacy in the real-world. The results of the evaluation were positive, which provides reasonable proof and new insights into the benefits of using MPCP to visually analyze high-dimensional geographical datasets

The efficacy and safety of combined therapy with endobronchial tamponade and bronchial artery embolization for massive hemoptysis

Abstract Background Massive hemoptysis is characterized by its life-threatening nature, potentially leading to airway obstruction and asphyxia. The objective of this study was to evaluate the clinical effectiveness of combining endobronchial tamponade with bronchial artery embolization (BAE) in the treatment of massive hemoptysis. Methods Between March 2018 and March 2022, a total of 67 patients with massive hemoptysis who underwent BAE were divided into two groups: the combination group (n = 26) and the BAE group (n = 41). Technical and clinical success rates were assessed, and adverse events were monitored following the treatment. Blood gas analysis and coagulation function indicators were collected before and after the treatment, and recurrence and survival rates were recorded during the follow-up period. Results All patients achieved technical success. There were no significant differences in the clinical success rate, recurrence rates at 3 and 6 months, and mortality rates at 3 months, 6 months, and 1 year between the combination group and the BAE group. However, the hemoptysis recurrence rate at 1 year was significantly lower in the combination group compared to the BAE group (15.4% vs. 39.0%, P = 0.039). No serious adverse events were reported in either group. After treatment, the combination group showed higher levels of arterial partial pressure of oxygen (PaO2), oxygenation index (PaO2/FiO2), fibrinogen (FIB), and D-dimer (D-D) compared to the BAE group (P < 0.05). Multivariate regression analysis demonstrated a significant correlation between combined therapy and hemoptysis-free survival. Conclusion Combination therapy, compared to embolization alone, exhibits superior efficacy in improving respiratory function, correcting hypoxia, stopping bleeding, and preventing recurrence. It is considered an effective and safe treatment for massive hemoptysis

HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial

Abstract Currently approved HER2-targeting antibody-drug conjugates (ADCs) for HER2-positive breast cancer (BC) are associated with safety concerns. In this multicenter, single-arm, dose-escalation (phase 1a) and dose-expansion (phase 1b) phase 1 trial (NCT03944499), patients with HER2-expressing advanced solid tumors received FS-1502 (an anti-HER2 ADC) with a 3 + 3 design in phase 1a; patients with metastatic HER2-positive BC received FS-1502 at the recommended phase 2 dose (RP2D) in phase 1b. The primary end points were dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and RP2D for phase 1a and objective response rate (ORR) for phase 1b. A total of 150 patients with HER2-expressing solid tumors (n = 5) and BC (n = 145) were enrolled (female, n = 146, 97.3%). One DLT each was reported at 3.0 and 3.5 mg/kg; the MTD was not reached. The RP2D was 2.3 mg/kg once every 3 weeks. Five (3.3%) patients experienced pneumonitis; four (2.7%) had grade 3 reversible ocular events. Of 67 HER2-positive BC patients receiving the RP2D, the best ORR was 53.7% (95% CI, 41.1-66.0%), including PRs confirmed (confirmed ORR, 37.5%) and pending for confirmation. FS-1502 was well tolerated with limited ocular and pulmonary findings and demonstrated promising antitumor activity in HER2-positive BC patients